Literature DB >> 8618161

Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts.

D R Clohisy1, C M Ogilvie, R J Carpenter, M L Ramnaraine.   

Abstract

The cellular and biochemical mechanisms that direct destruction of bone at the site of tumor osteolysis are unknown. In order to understand this process better, a murine model designed for the study of tumor osteolysis was developed and the influence of osteolytic and nonosteolytic tumors on bone was investigated. Tumors developed following femoral intramedullary injection of sarcoma (2472) and melanoma (G3.26) cell lines; however, only tumors from the 2472 cell line caused osteolysis. It was determined that 2472 tumor-induced osteolysis commenced 6 days after the femora had been inoculated with 2472 cells. There were more osteoclasts per millimeter of bone surface in 2472 tumor-bearing limbs (16.7 +/- 5.0) than in sham-injected limbs (3.8 +/- 0.9) (p < 0.015). In addition, an increase in the osteoclast size (area) was detected in 2472 tumor-bearing limbs: 412 +/- 65 micron2 compared with 187 +/- 17 micron2 (p < 0.01). In vitro bone resorption experiments indicated that 2472 tumor cells had a limited ability to destroy bone in comparison with macrophages and osteoclasts. Taken in total, these findings define a model that is useful for the study of tumor osteolysis, and the data from analyses of the model demonstrate that the cellular mechanisms responsible for 2472 tumor-induced osteolysis include both an increase in the number of osteoclasts and activation of mature osteoclasts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8618161     DOI: 10.1002/jor.1100140103

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  23 in total

Review 1.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

2.  Metabolic activation stimulates acid secretion and expression of matrix degrading proteases in human osteoblasts.

Authors:  M George; B Stein; O Müller; M Weis-Klemm; T Pap; W J Parak; W K Aicher
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

3.  Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain.

Authors:  M J Schwei; P Honore; S D Rogers; J L Salak-Johnson; M P Finke; M L Ramnaraine; D R Clohisy; P W Mantyh
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

Review 4.  Metastatic bone cancer pain: etiology and treatment options.

Authors:  Gary C O'Toole; Patrick Boland
Journal:  Curr Pain Headache Rep       Date:  2006-08

5.  Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.

Authors:  Darryl T Hamamoto; Subhalakshmi Giridharagopalan; Donald A Simone
Journal:  Eur J Pharmacol       Date:  2006-12-09       Impact factor: 4.432

6.  Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain.

Authors:  P W Wacnik; L J Eikmeier; T R Ruggles; M L Ramnaraine; B K Walcheck; A J Beitz; G L Wilcox
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

7.  Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain.

Authors:  D M Cain; P W Wacnik; M Turner; G Wendelschafer-Crabb; W R Kennedy; G L Wilcox; D A Simone
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

8.  Intrathecal administration of Resolvin D1 and E1 decreases hyperalgesia in mice with bone cancer pain: Involvement of endocannabinoid signaling.

Authors:  Iryna A Khasabova; Mikhail Y Golovko; Svetlana A Golovko; Donald A Simone; Sergey G Khasabov
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-07-31       Impact factor: 3.072

9.  Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer.

Authors:  Tamara King; Anna Vardanyan; Lisa Majuta; Ohannes Melemedjian; Ray Nagle; Anne E Cress; Todd W Vanderah; Josephine Lai; Frank Porreca
Journal:  Pain       Date:  2007-08-15       Impact factor: 6.961

10.  NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use.

Authors:  Gwen McCaffrey; Michelle L Thompson; Lisa Majuta; Michelle N Fealk; Stephane Chartier; Geraldine Longo; Patrick W Mantyh
Journal:  Cancer Res       Date:  2014-10-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.